Gene therapy registry tracks lifelong safety for rare immune disorder
NCT ID NCT03478670
First seen May 19, 2026 · Last updated May 20, 2026 · Updated 1 time
Summary
This study follows 50 people with ADA-SCID, a severe immune disorder, who received Strimvelis gene therapy. Researchers will monitor participants for years to check for side effects, immune function, and overall health. The goal is to understand the long-term safety and how well the therapy works.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IMMUNOLOGIC DEFICIENCY SYNDROMES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Ospedale San Raffaele
Milan, Lombardy, 20132, Italy
Conditions
Explore the condition pages connected to this study.